BayHelix 11th Annual Conference

-- Leading Changes in Life Sciences Across the Pacific

January 12, 2014 (Sunday)

William J. Rutter Center

San Francisco Mission Bay
1675 Owens Street
San Francisco, California 94158

Chairperson:
Jimmy Z. Zhang, PhD, MBA
 Draft Schedule

8:30 - 9:00 am Registration and Socialization

9:00 - 9:20 am Welcome Remark, “BayHelix Past, Present, and Future”

Jimmy Z. Zhang, PhD, MBA
Chairman, BayHelix Board of Directors

9:20 - 10:10 am Keynote Speech

“Convergence in Healthcare”
Lee Babiss, PhD
Chief Scientific Officer, EVP of Discovery Innovation, PPD
Chief Executive officer, X-Rx

10:10 - 10:30 am Tea Break

10:30 - 11:35 am Panel Discussion

“Leading Changes in Life Sciences Across the Pacific, Right on the
Curve”
Moderator: Jay Dong, General Manager, Asia Pacific, Cell
Signaling Technology
Panelists:
Samantha Du, Managing Director, Sequoia Capital China
Jay Qin, CEO, MedSphere Int'l Holdings
Alan Paau, Executive Director & Vice Provost, Cornell University
Greg Scott, CEO, ChinaBio LLC

11:35 am - 12:25 pm Keynote Speech

“Recent Trends for Licensing and M&A in the Life Sciences
Sector in the US, Europe and Asia”
David Schulman, Partner, Dechert
Emmanuelle Trombe, Partner, Dechert
Lewis Ho, Partner, Dechert

12:25 - 1:45 pm On-site Buffet Lunch

BayHelix Board Transition
1:45 - 2:00 pm Presentation by Sponsors

2:00 - 2:05 pm BayHelix Lifetime Achievement Award Ceremony

2:05 - 2:55 pm BayHelix Lifetime Achievement Award Speech

“Life Science, a Life in Science, and in Life Just a Science”
Gerald Chan, PhD
Co-founder, Morningside Group

2:55 - 3:15 pm Tea Break

3:15 - 4:05 pm Keynote Speech

“Medicines Discovery, Development and Access - Addressing the
Need of Society”
Zhi Hong, PhD, Senior Vice President
Head of Infectious Diseases Therapy Area Unit
Head of virtual Liver Unit
GSK

4:05 - 5:10 pm Panel Discussion II

“Recent Trends for Investment in the Life Sciences Sector in
China”
Moderator: Lewis Ho - Partner, Dechert
Panelists:
Ian Woo - Managing Director, Lazard
Lawrence Wang - Managing Director, Primavera Capital Group
Helen Chen - (Head of China Healthcare) LEK Consulting

5:10 - 6:10 pm Reception

6:15 - 9:30 pm BayHelix Members Only Discussion

1) Industry and Me
2) BayHelix future direction
3) BayHelix branding and positioning

BayHelix 11th Annual Conference Preparation Committee:

Jun Bao, Jay Dong, Yun He, Darren Ji, Alan Paau, Greg Scott, Lin Sun-Hoffman, Yingfei Wei, Marietta
Wu, Guo-Liang Yu, Jimmy Zhang, Tony Zhang
BayHelix Lifetime Achievement Award

Dr. Gerald Chan

Co-Founder, Morningside Group

Gerald Chan is the co-founder of Morningside, an international investment group with private
equity, venture capital and property investments. The group's technology venture portfolio is
spread across life science, the Internet, and clean energy sectors.

In the life science sector, Morningside focuses on start-up biotechnology companies founded
on novel scientific discoveries. He serves on the boards of Advanced Cell Diagnostics, a
molecular tools and diagnostics company, Oxyrane which develops new methods for
manufacturing therapeutic proteins, Stealth Peptides which develops mitochondria-targeting
therapeutics, Synchroneuron which develops CNS drugs, Apellis, which develops complement
inhibitors, and the vaccine companies VTI and Matrivax.

Gerald serves on the Global Advisory Council of the International Society for Stem Cell Research,
the International Board of Governors of the New York Academy of Sciences, the Global Advisory
Council of Harvard University, the Dean's Board of Advisors of the Harvard School of Public
Health and the advisory boards of the Cold Spring Harbor Conferences Asia, the Johns Hopkins
Nanjing Center and the Columbia University Center for Radiological Research. He is a trustee of
Fudan University in Shanghai and chairs the Board of Overseers of the Morningside College of
the Chinese University of Hong Kong. He is a member of the Council on Foreign Relations, New
York.
He received his BS and MS degrees in engineering from UCLA, his Master's degree in medical
radiological physics and Doctor of Science degree in radiation biology from Harvard University.
He did his post-doctoral training at the Dana-Farber Cancer Institute as a fellow of the Leukemia
Society of America. In 2011, the Chinese University of Hong Kong conferred on him an honorary
Doctor of Social Science degree. He was the commencement speaker of the Harvard School of
Public Health in 2012 and was elected to an honorary fellowship at Wolfson College of Oxford
University in 2013.
Keynote Speakers

Lee Babiss, PhD

Chief Scientific Officer, EVP of Discovery Innovation, PPD
Chief Executive officer, X-Rx

Lee Babiss, Ph.D., is PPD’s chief scientific officer, executive vice president of discovery
innovation and chief executive officer of X-Rx. In these roles, he provides insight and guidance
regarding scientific matters across all PPD business units as well as strategic leadership to the
company’s discovery innovation business.

Babiss joined PPD in 2010 with more than 21 years of experience in leading R&D efforts in
support of drug discovery. He most recently served as president and director of pharmaceutical
research for F. Hoffmann-La Roche Ltd., in Basel, Switzerland, where his responsibilities
included leading global laboratory functions in chemistry, discovery technologies, therapeutic
proteins, non-clinical safety and informatics. He supported drug discovery efforts in oncology,
neurosciences, inflammation, virology and metabolism, and was a member of the company’s
pharma executive and strategic portfolios committees.

Prior to joining Hoffmann-La Roche, Babiss spent seven years with Glaxo Inc., now
GlaxoSmithKline. As vice president of biological sciences and genetics, he had global
accountability for developing and implementing the company’s corporate genetics strategy and
oncology research efforts focused on the cell cycle.

Babiss earned a doctorate in microbiology from Columbia University and completed his
postdoctoral fellowship at The Rockefeller University, where he served as an assistant and
associate professor. He has published more than 60 peer-reviewed scientific papers, received
numerous fellowship awards and grants, and serves on several scientific advisory committees
and boards.
David E. Schulman
Partner, Dechert

David E. Schulman advises life sciences companies, financial institutions, private equity fund
sponsors, and venture capital firms in both the United States and Europe on corporate and
securities matters. Mr. Schulman has extensive experience representing public and private
companies, particularly in the life sciences and investment management sectors, in connection
with acquisitions, divestitures, and other significant corporate transactions, including tender
offers, stock-for-stock mergers, proxy contests, cash mergers, spin-offs, restructurings, stock
and asset acquisitions and dispositions, and troubled company M&A and bankruptcy-related
transactions. He also frequently advises life sciences and other technology-based companies on
domestic and cross-border collaborations, co-promotions, licenses, and distribution
arrangements.

Mr. Schulman has been ranked among the top lawyers globally for life sciences by leading legal
directory Chambers Global, where he is praised for being “one of the best business and
corporate lawyers in the life sciences sector” with “a deep knowledge of the industry, which he
successfully combines with great legal skills.” Mr. Schulman has also been recognized for his
work in healthcare: life sciences and for mergers and acquisitions by legal directory The Legal
500 (U.S.), where he is cited for his “ability to mediate in difficult commercial negotiations
between the parties.” In addition, he has been recommended for life sciences: commercial and
partnering matters in the United States by Practical Law Company.

Mr. Schulman was based in Dechert’s London office for seven years and currently divides his
time between the firm’s London and Washington, D.C. offices. He is co-head of the firm’s Life
Sciences practice.
Emmanuelle Trombe
Partner, Dechert

Emmanuelle Trombe practices in the areas of corporate and general commercial law, with a
focus on the pharmaceutical, medical device and healthcare industries.

Ms. Trombe has significant experience both in France and in the U.S. assisting clients with large-
scale, international projects. She represents pharmaceutical, medical device and bio-
pharmaceutical companies in relation to:

 Acquisitions and divestitures

 Outsourcing projects

 Product development

 Licensing agreements

 Pharmaceutical regulatory matters

 General corporate and commercial law matters

Ms. Trombe also represents VC funds and bio-pharmaceutical companies in connection with
financing rounds, including the IPO process.

Listed in Chambers Europe 2011 for Pharma-Life Sciences in France, Ms. Trombe is “a corporate
and commercial expert [who] is also an established figure in the life sciences field. She assists
U.S. and French pharmaceutical, medical device, and bio-pharmaceutical companies with issues
including acquisitions and divestitures, outsourcing projects, product development and
licensing agreements.”
Lewis Ho
Partner, Dechert

Lewis Ho leads the life sciences practice in Asia. He helps life sciences and technology
companies and their financial sponsors to capture, manage, risk assess, evaluate and monetize
their intellectual property assets. His practice focuses on structuring technology transfer
transactions and enforcing intellectual property rights.

Mr. Ho has extensive experience advising on both inbound and outbound technology transfer
transactions, and has negotiated more than 40 collaboration, outsourcing, joint venture and
licensing deals with various life sciences companies, academic institutes, hospitals and contract
research organizations in the last few years.

Mr. Ho has been recognized by Chambers Asia and Legal 500 as one of the leading life sciences
and IP lawyers in China. In the 2012 edition of Chambers Asia, clients described him as
“professional and prompt in providing feedback” and as producing “a high quality of work.” He
was also included in two 2012 Intellectual Asset Management magazine lists: “The World’s
Leading Patent Practitioners 1000,” where he is recommended in both the licensing and
litigation sections, and “Life Sciences 250—The World’s Leading Life Sciences Patent Litigators.”
He is also recommended by The International Who’s Who Legal 2013 as a life sciences lawyer
for intellectual property, regulatory and transactional advice in China. Mr. Ho is frequently
invited to speak on life sciences and intellectual property issues at conferences and seminars.

Prior to joining Dechert, Mr. Ho served as a resident partner in the Shanghai and Beijing offices
of a major international law firm.
Zhi Hong, PhD
Senior Vice President
Head of Infectious Diseases Therapy Area Unit
Head of virtual Liver Unit
GSK

Dr. Zhi Hong is the Senior Vice President, Head of the Infectious Diseases (ID) Therapy Area Unit
at GSK. He is accountable for designing, developing and delivering the end-to-end R&D strategy
and pipeline. Zhi is a Board member of ViiV Healthcare, a specialist HIV company established by
GSK and Pfizer. He is a member of the Microbial Threats Forum at the Institute of Medicine.
Under his leadership, GSK ID pipeline has been revitalized since 2007 with the recent approval
of Tivicay, an HIV medicine. Prior to joining GSK, Zhi was the Chief Scientific Officer and
Executive Vice President at Ardea Biosciences, a biotech company acquired by AstraZeneca. Zhi
has many years of experience in drug discovery and product development. He is a public health
advocate and has helped to establish multiple public private partnerships with US Government,
European Commission and Philanthropic Organizations. Zhi has extensive business
development experience and invested/divested broadly through various innovative
transactions and start-ups. He received a Bachelor of Science degree from Fudan University at
Shanghai, China and his Ph.D from the State University of New York at Buffalo.
Panelists

Helen Chen, MBA

Head of China Healthcare, LEK Consulting

Jay Dong
General Manager, Asia Pacific, Cell Signaling Technology
Jay Dong is General Manager, Asia Pacific Region, Cell Signaling
Technology (CST), Inc., Danvers/Boston, MA, USA. Jay is also the founding
General Manager of CST (Shanghai) Biological Reagents Company, the
China subsidiary of Cell Signaling Technology, Inc. Jay has successfully
built CST China business and a professional team of Marketing, Sales,
Channel Management, Technical Support, Applications, Logistics and
Warehouse Management, HR, and Customer Care during the past few
years. Today, CST is well recognized as the “Golden Standard” of its kind
by many customers across China.
Before joining CST, Jay was with Becton Dickinson and Company, as US Marketing Manager and
Asia Pacific Business Manager, in the US and in Singapore. He is a graduate of Tufts University
Fletcher School, in Boston, USA, and of Peking Union Medical College-Faculty of Medicine of
Tsinghua University, in Beijing, China. Jay has served as a Board Director of Sino-American
Biotechnology and Pharmaceutical Professionals Association (SABPA) in San Diego (2004-2006),
and as a Board Director of CST Japan (2009/2010). Jay is an elected Board member of BayHelix
Group, and also serves as Vice Chairman of the Board.

Samantha Du, PhD

Managing Director, Sequoia Capital China
Samantha Du, Managing Director of Sequoia Capital China, focuses on
healthcare investment. Prior to joining Sequoia in 2012, Dr. Du was the
founder and CEO of Hutchison MediPharma Limited since 2001. She also
co-founded Hutchison China MediTech Limited, where she acted as its CSO
and played a key role in its successful IPO on UK Aim market. Before
Hutchison MediPharma, Dr. Du worked at Pfizer US, where she was
responsible for global metabolic diseases licensing on the scientific side.
Samantha started her industry career at Pfizer US global R&D headquarter,
where she led teams involved in drug development in various stages and therapeutic areas, two
of the products she worked on had received global regulatory approval and launch. Dr. Du
received her Ph.D. in Biochemistry from University of Cincinnati. She is currently an adjunct
professor at Fudan University and chairwoman of shanghai pudong drug innovation consortium.
She is a recipient both of thousand talent program in shanghai and of shanghai Magnolia award.
She is on the board of BGI tech, JHL biotech, Beta Pharma.

Alan Paau, PhD, MBA

Executive Director & Vice Provost, Cornell University
Dr. Paau is responsible for the strategic management of all technologies
and intellectual property that arise from the research activities at Cornell
University - both at the Weill Medical College in New York City and at the
general campus in Ithaca.
Prior to joining Cornell in January 2007, Dr. Paau for nine years was
Director and Assistant Vice Chancellor for Technology Transfer &
Intellectual Property Services at the University of California, San Diego (San
Diego, CA). From 1994 to 1998, he was Executive Director of the Iowa
State University Research Foundation, Inc. and Director of Intellectual
Property & Technology Transfer at Iowa State University (Ames, IA). Until
1994, he was Associate Director of the Biotechnology Center at the Ohio State University
(Columbus, OH) with responsibilities in research, teaching, research administration, technology
management, and industry liaison.
Dr. Paau held faculty appointments while at Iowa State University in the departments of
Preventive Medicine, Immunology & Microbiology, and Genetics & Zoology, and at the Ohio
State University in the departments of Microbiology, and Plant Pathology.
Before returning to the academic environment in 1992, Dr. Paau held various research and
management positions of increasing responsibilities in the Cetus Corporation and the W.R.
Grace & Co. organizations for 12 years and led the development of two commercial products.
Dr. Paau holds a Ph.D. degree in Biological Sciences and a Master of Business Administration
degree. He also attended the Drake University School of Law. Dr. Paau is the inventor to 8 US
patents with foreign equivalents and has contributed thirty peer-reviewed research articles to
scientific journals and six invited reviews and chapters to technical books.
Dr. Paau speaks often at professional seminars and international conferences and currently
serves on the Boards of Directors of The BayHelix Group, Vivo Development, Inc.,
NanoTecNexus, and the Cornell Research Foundation, Inc. where he also serves as its president.
Dr. Paau currently serves as an advisor to the Big Red Consultants, the China Medical City,
Startup World Cup – New York Region, Chinese Association for Science and Business, and NYC
BIO. As a director of intellectual property, a licensing executive, and a Certified Licensing
Professional,* he has supervised the execution of over 1600 technology transactions and the
formation of over 140 startup companies using licensed technologies. Recognitions of his
contributions to the technology management and community development efforts include the
2006 San Diego Bio-Pharma Award (SABPA), the 2005 Vision Award (SDCA), listing in 2004
Jay Qin
CEO, Founder and Chairman of Shanghai Kinetic Medical Co., Ltd.
Mr. Qin is founder and Chairman of Shanghai Kinetic Medical Co., Ltd.
(300326), a leading developer and manufacturer of minimally invasive
orthopedic and cardiovascular devices. Mr. Qin is also the founder and
Chairman of MedSphere International Holdings, Inc., a Shanghai based
developer and manufacturer of RF equipment for minimally invasive
surgeries.
Prior to his business venture in China, he had been involved in several
successful medical device startups in the US. He held engineering and
management positions at Medtronic and B. Braun early in his career.
Mr. Qin holds a B.S. in Electrical Engineering from Fudan University and a
M.S. in Biomedical Engineering from the Ohio State University. He has over 30 US and Chinese
patents issued to his credit.

Greg B. Scott
President and Founder, ChinaBio® LLC

Greg Scott founded ChinaBio® LLC in January 2007 to bring together

Chinese and Western life science companies to better leverage China’s
rapidly growing life science markets. ChinaBio works with U.S. and
European companies seeking partnerships, acquisitions, novel
technologies and funding in China. ChinaBio has also organized over 30
conferences in China focused on investment and partnering, and is
holding its sixth ChinaBio Partnering Forum in Suzhou on May 7-8, 2014.
This international event draws over 800 attendees from around the
world, making it the largest partnering conference in China. Greg is also co-founder of two
angel investment groups that have funded over 45 biotechnology and medical device
companies in the U.S. and China since 2005, and Executive Editor of ChinaBio® Today, the most
widely read source for China life science news. Greg lives and works in Shanghai but visits the
U.S. several times a year to enjoy California’s blue sky and sandy beaches.

Lawrence Wang, MBA

Managing Director, Primavera Capital Group

Lawrence is currently managing director and head of healthcare for Primavera Capital. Previous
to joining Primavera, he was Head of Asia Healthcare for Macquarie Capital and prior to
Macquarie, was an Executive Director in Goldman Sachs with roles in GS Direct Asia in Hong
Kong and healthcare investment banking both in Hong Kong and New York.

Lawrence holds a Bachelor of Arts in Biology and Economics and a Doctor of Medicine from
Boston University and an MBA from MIT Sloan School of Management.

Ian Woo
Managing Director, Lazard

Jimmy Z. Zhang, PhD, MBA

Managing Director, MSD Early Investments – Greater China, Merck & Co.
Dr. Jimmy Zhang is the Managing Director, MSD Early Investments – Greater China at Merck &
Co. He's responsible for Merck's venture capital investments, licensing, acquisitions, external
research collaboration, and alliance/partnership management in Greater China.
Before joining Merck/MSD, Jimmy was a Senior Vice President at Synergenics, LLC, a
professional service and venture firm founded and led by Dr. Bill Rutter, one of the founding
fathers and pioneers of the biotech industry. Synergenics invests and manages early-stage
companies in drug discovery, vaccine, diagnostics, and healthcare IT.
Jimmy is responsible for the business development and operations of
Synergenics and some of its portfolio companies, and their businesses in
China. Jimmy was previously a consultant at McKinsey & Company, a
registered patent agent in the Palo Alto office of Morrison & Foerster, and
a project manager at Chiron Corporation (now part of Novartis).
Jimmy received his B.S. in biochemistry from Nanjing University, and Ph.D.
in biomedical sciences from the University of Texas Southwestern Medical
Center at Dallas, where he worked closely with three Nobel Laureates.
While studying his MBA in MIT Sloan School of Management, Jimmy was elected as the
treasurer of MIT Graduate Student Council. He was also a finalist of the 12th Annual MIT $50K
Entrepreneurship Competition.
Jimmy is a founding member and the current Chairman, Board of Directors of BayHelix Group, a
prestigious non-profit organization of Chinese life sciences business leaders. Jimmy is also the
Strategic Advisor to both ChinaSF and China Committee of Bay Area Council, and a
guest/adjunct professor at Tongji University, Shanghai.
Specials Thanks to Our Sponsors

BayHelix Sponsor (Platinum Level)

DoubleHelix Sponsor (Gold Level)

Helix Sponsor (Silver Level)

 Supported By

Official Partners

Publicity Partners
 Parking Instruction
(1670 Owen Parking Garage behind Gladstone building)
From San Francisco Downtown/Civic Center:

1. Take 8th Street south from Market Street.

2. Turn left on Brannan Street.
3. Turn right on 7th Street.
4. Turn left on 16th Street.
5. Go one block and turn left on Owens Street.
6. Rutter Center will be on the right-hand side
7. 1670 Owen Parking Garage will be on the left side left (west) side of Owens Street after having passed the Gladstone
building (the second building on the left). No free parking in the garage attached to Rutter Center

From the South Bay/San Francisco Airport:

1. From 101 or 280 Freeway North:

2. Take the 280 freeway toward Downtown San Francisco
3. Exit 280 at Mariposa Street and Turn Right
4. Turn Left at Third Street
5. Go two blocks to 16th Street
6. Turn left at 16th and go two blocks to Owens Street
7. Turn right at Owens street
8. Rutter Center will be on the right-hand side
9. 1670 Owen Parking Garage will be on the left side left (west) side of Owens Street after having passed the Gladstone
building (the second building on the left). No free parking in the garage attached to Rutter Center

From the East Bay/Bay Bridge:

1. After crossing the Bay Bridge, exit at 9th Street/Civic Center.

2. Turn left on 8th Street at the bottom of the exit ramp.
3. Turn left on Brannan Street.
4. Turn right on 7th Street.
5. Turn left on 16th Street.
6. Go one block and turn left on Owens Street.
7. Rutter Center will be on the right-hand side
8. 1670 Owen Parking Garage will be on the left side left (west) side of Owens Street after having passed the Gladstone
building (the second building on the left). No free parking in the garage attached to Rutter Center

From the North Bay/Golden Gate Bridge:

1. After crossing the Golden Gate Bridge, drive east on 101 (Doyle Drive) towards downtown San Francisco.
2. Exit at Marina Boulevard.
3. Follow Marina Boulevard past Fort Mason.
4. Turn left on Bay Street.
5. Turn right on The Embarcadero.
6. After passing under the Bay Bridge, The Embarcadero will become King Street.
7. Turn left on 3rd Street just past SBC Baseball Park.
8. Cross the 3rd Street (Lefty O'Doul) Bridge and continue south on 3rd Street.
9. Turn right on 16th Street.
10. Turn right on Owens Street (2nd available right turn after 3rd Street).
11. Rutter Center will be on the right-hand side
12. 1670 Owen Parking Garage will be on the left side left (west) side of Owens Street after having passed the Gladstone
building (the second building on the left). No free parking in the garage attached to Rutter Center
1670 Owens Street Parking Garage Access

1. Once on Owens Street, make the first left at STOP sign, just after the J. David
Gladstone Institute Building.
2. Turn left at the end of the short road to find the entrance to the parking garage.
3. To enter the garage, use the machine at the entrance gate to obtain a parking ticket.
4. To exit the garage, insert your entrance ticket followed by the validation ticket,
provided at BayHelix registration, into the payment machine.

Public transit

The UCSF Mission Bay campus is served by the Muni T-Third Street line, which stops
at the UCSF Mission Bay Station located on Third Street near 16th Street. This applies
for both north- and southbound travel — that is, going downtown or out to San
Francisco's southeast neighborhoods. From Downtown, taking Muni KT/Third Street
line labeled with Inbound to Sunnydale & Bayshore. After getting off T, look for the red-
brown color building with the green on the top, which is the William J. Rutter Center.
Registration:

1. Space is extremely limited. We’ll have to close registration if we have reached capacity.
Please register early
2. Please register yourself for the annual conference at www.bayhelix.org
3. Please register yourself to the website first. Create your username and password, and use
11thAnnualConf@bayhelix.org or your email address as the email address for the initial
registration 4. Select Member Center -> Events Management -> January 2014, and click 11th
BayHelix Annual Conference hyperlink on January 12 calendar
4. Please follow the annual conference registration process, and register yourself. At this stage,
you may change the email to your own preferred email address (there are several places you
need to change to your own email address)
5. Lunch, tea breaks and reception are provided.

Please let Iris (irisc_2010@yahoo.com) know if you encounter any issues during registration.

BayHelix:

BayHelix is an organization of leaders of Chinese heritage in the global life sciences and
healthcare community. We aspire to shape the growth of the life sciences and healthcare
industry around the Pacific Rim and beyond, foster and create business opportunities, supply
and nurture the leaders for the community, and network and share information and experience.
BayHelix is a non-profit organization and its membership is by-invitation-only.

Since our inception in 2001, we have been steadily growing our membership to over 500
members throughout the United States, Canada, Europe, and Greater China. Our membership
base covers virtually all of the world’s top pharmaceutical and biopharmaceutical companies,
and strong presences in professional services, including consulting, investment banking,
venture capital, private equity, and legal services. Our members are experienced business
professionals, and almost all of them hold leadership positions within their organizations and
have strong relationships with other senior executives in the industry. More than one third of
our members are “C-level” executives (CEO, CFO, COO, etc.). The R&D heads of most MNC
pharmaceutical companies in China/Asia are BayHelix members.